A Study of PYX-201 in Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Solid Tumor, Advanced Solid Tumor
In brief
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Key facts
- Study ID
- NCT05720117
- Run by
- Pyxis Oncology, Inc
- People needed
- 330
- Starts
- 2023-03-14
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-06-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States (enrolling)
- Ronald Reagan UCLA Medical Center — Los Angeles, California, United States (enrolling)
- SCRI - HealthOne Denver — Denver, Colorado, United States (enrolling)
- SCRI - Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
- University of Chicago Medicine — Chicago, Illinois, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- University of Cincinnati Medical Center — Cincinnati, Ohio, United States (enrolling)
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- Rhode Island Hospital — Providence, Rhode Island, United States (enrolling)
- NEXT Dallas — Dallas, Texas, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- NEXT San Antonio — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Institut Jules Bordet — Brussels, Brussels Capital, Belgium (enrolling)
- Cliniques Universitaires Saint-Luc — Brussels, Brussels Capital, Belgium (enrolling)
- Universitair Ziekenhuis Antwerpen — Edegem, Edegem, Belgium (enrolling)
- Universitair Ziekenhuis Gent — Ghent, Gent, Belgium (enrolling)
- Hospital Universitari Vall d'Hebrón — Barcelona, Barcelona, Spain (enrolling)
- START Madrid - Hospital Universitario Fundación Jiménez Díaz — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario HM Sanchinarro — Madrid, Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.